Antiviral Drugs - New Zealand

New Zealand

The Antiviral Drugs market in New Zealand is anticipated to witness a significant growth in revenue, with projections indicating a rise to US$55.88m in 2024.
Moreover, it is expected to maintain a steady upward trajectory, showcasing an annual growth rate of 1.82% (CAGR 2024-2029).
This positive trend is likely to culminate in a market volume of US$61.16m by 2029.
When considering global comparisons, it is noteworthy that United States is anticipated to contribute the highest revenue in the market, with an estimated figure of US$30,640.00m in 2024.
New Zealand's pharmaceutical industry is witnessing a surge in demand for antiviral drugs due to the country's proactive approach in combating infectious diseases.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in New Zealand has been steadily growing over the years.

Customer preferences: New Zealand has a universal healthcare system that is funded by the government, which means that the majority of the population has access to affordable healthcare. As a result, the demand for antiviral drugs in New Zealand is largely driven by the prevalence of viral infections such as influenza and hepatitis.

Trends in the market: One of the major trends in the Antiviral Drugs market in New Zealand is the increasing use of combination therapies. Combination therapies involve the use of two or more antiviral drugs to treat a viral infection. This approach has been shown to be more effective than using a single antiviral drug, and it has become increasingly popular in New Zealand in recent years. Another trend in the market is the growing use of antiviral drugs for the treatment of HIV/AIDS. The introduction of highly active antiretroviral therapy (HAART) has significantly improved the prognosis for people living with HIV/AIDS in New Zealand, and this has led to an increase in the demand for antiviral drugs.

Local special circumstances: New Zealand has a small population of just over 5 million people, and this has implications for the Antiviral Drugs market. Pharmaceutical companies may be less likely to invest in the development of new antiviral drugs specifically for the New Zealand market, as the potential market size is relatively small. However, the government of New Zealand has a Pharmaceutical Schedule, which lists the medicines that are subsidized by the government. This means that antiviral drugs that are listed on the Pharmaceutical Schedule are more accessible and affordable for the majority of the population.

Underlying macroeconomic factors: The Antiviral Drugs market in New Zealand is influenced by a range of macroeconomic factors. One of the key factors is the level of government funding for healthcare. As the government is the primary funder of healthcare in New Zealand, any changes to healthcare funding can have a significant impact on the Antiviral Drugs market. Another factor is the level of competition in the market. The Antiviral Drugs market in New Zealand is relatively small, and there are a limited number of companies that are active in the market. This can lead to higher prices for antiviral drugs, as there is less competition to drive prices down. Finally, the level of research and development in the pharmaceutical industry can also have an impact on the Antiviral Drugs market in New Zealand. If there is a lack of investment in the development of new antiviral drugs, this can limit the availability of new treatments for viral infections in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.